Inventor · disambiguated record
Harold Keer
Also filed as: KEER HAROLD
5 granted patents·6 pending applications·13 citations·filing 2011–2023
70Inventor score
Top patents by PatentIndex Score
11 records- 0184US8481038B2Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteinsKEER HAROLD·Filed 2011·Granted Jul 9, 2013·13 cites·22 claims
- 0270US11660310B2Low dose combination CDA substrate drug/cedazuridine with extended administrationOTSUKA PHARMA CO LTD·Filed 2021·Granted May 30, 2023·0 cites·19 claims
- 0370US2023270771A1Low dose combination cda substrate drug/cedazuridine with extended administrationOTSUKA PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 0469US11224610B2Low dose combination CDA substrate drug/cedazuridine with extended administrationOTSUKA PHARMA CO LTD·Filed 2019·Granted Jan 18, 2022·0 cites·10 claims
- 0567US9475871B2Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2014·Granted Oct 25, 2016·0 cites·22 claims
- 0660US2024082286A1Combination therapies for treatment of t-cell lymphomasOTSUKA PHARMA CO LTD·Filed 2023·Application pending·0 cites
- 0758US8920800B2Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteinsFIVE PRIME THERAPEUTICS INC·Filed 2013·Granted Dec 30, 2014·0 cites·31 claims
- 0857US2025000888A1Methods of treating myelodysplastic syndromes with decitabine and cedazuridineOTSUKA PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 0953US2023338342A1Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitorTAIHO PHARMACEUTICAL CO LTD·Filed 2021·Application pending·0 cites
- 1047US2023405037A1Pharmaceutical compositions and methods of using the same for treating cancerOTSUKA PHARMA CO LTD·Filed 2021·Application pending·0 cites
- 1145US2020352976A1Hypomethylating agents for use in treatment of cancerOTSUKA PHARMA CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Harold Keer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →